Shilpa Medicare Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Shilpa Medicare şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

-6.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-6.3%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	₹1.100
Ödeme oranı	0%

Son temettü ve geri alım güncellemeleri

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Sep 07

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Aug 14

Recent updates

What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You

Sep 12

Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues

Jul 05

What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Apr 12

Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Feb 21

Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

Jan 02

These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

Jul 17

Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Mar 17

Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Sep 22

Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Sep 21

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jun 17

If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late

May 31

Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Mar 07

Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year

Feb 20

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jan 26

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: SHILPAMED şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: SHILPAMED şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Shilpa Medicare Piyasaya Karşı Temettü Getirisi

SHILPAMED temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (SHILPAMED)	0%
Pazarın Alt %25'i (IN)	0.2%
Pazarın En İyi %25'i (IN)	1.1%
Sektör Ortalaması (Pharmaceuticals)	0.7%
Analist tahmini (SHILPAMED) (3 yıla kadar)	0%

Önemli Temettü: SHILPAMED şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, SHILPAMED şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: SHILPAMED Indian piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: SHILPAMED herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Shilpa Medicare Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Shilpa Medicare Approves Dividend for the Financial Year Ended 31 March 2022

Upcoming dividend of ₹1.10 per share

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Upcoming dividend of ₹1.10 per share

Shilpa Medicare Limited Recommends Dividend for the Financial Year 2020-2021

Recent updates

Second quarter 2025 earnings released: EPS: ₹1.83 (vs ₹0.19 in 2Q 2024)

Shilpa Medicare Limited to Report Q2, 2025 Results on Nov 13, 2024

Shilpa Medicare Limited's CDMO Customer Receives Fast-Track Designation for Its Investigational Drug Candidate

What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You

Shilpa Medicare Limited Completes Phase 1 Trial for Recombinant Human Albumin (rHA) 20%

Shilpa Medicare Limited Announces the Approval of Its Second Nda, Injection, by Usfda

Shilpa Medicare Limited, Annual General Meeting, Sep 17, 2024

First quarter 2025 earnings released: EPS: ₹1.46 (vs ₹0.14 in 1Q 2024)

Shilpa Medicare Limited, Annual General Meeting, Sep 17, 2024

Shilpa Medicare Limited to Report Q1, 2025 Results on Aug 08, 2024

Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues

Full year 2024 earnings released: EPS: ₹3.67 (vs ₹3.74 loss in FY 2023)

Shilpa Medicare Limited to Report Q4, 2024 Results on May 23, 2024

What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Shilpa Medicare Limited has filed a Follow-on Equity Offering in the amount of INR 5 billion.

Shilpa Medicare Limited has filed a Follow-on Equity Offering in the amount of INR 5 billion.

Shilpa Medicare Limited has filed a Follow-on Equity Offering in the amount of INR 5 billion.

Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Third quarter 2024 earnings released: EPS: ₹0.53 (vs ₹0.76 loss in 3Q 2023)

Shilpa Medicare Limited to Report Q3, 2024 Results on Feb 08, 2024

Shilpa Medicare Limited and Celltrion, Inc. Announce Arbitration

Shilpa Medicare Limited and Celltrion, Inc. Announce Arbitration

Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

Second quarter 2024 earnings released: EPS: ₹0.19 (vs ₹2.15 loss in 2Q 2023)

Shilpa Medicare Limited to Report Q2, 2024 Results on Nov 10, 2023

Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal

Shilpa Medicare Limited, Annual General Meeting, Sep 29, 2023

First quarter 2024 earnings released: EPS: ₹0.14 (vs ₹0.10 in 1Q 2023)

Shilpa Medicare Limited to Report Q1, 2024 Results on Aug 10, 2023

These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

New minor risk - Share price stability

Full year 2023 earnings released: ₹3.74 loss per share (vs ₹7.26 profit in FY 2022)

Shilpa Medicare Limited Announces New Drug Application for Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 mg/50 mg & 100 mg/10 mg/10 mgl, Ready to Use Form Form Formulation Is Approved By US FDA

Shilpa Medicare Limited Announces US FDA GMP Inspection Cleared with VAI Classification

Shilpa Medicare Limited to Report Q4, 2023 Results on May 25, 2023

Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Shilpa Medicare Limited, Unit Vi, Bengaluru Facility Has Successfully Registered with Ministry of Health, United Arab Emirates

Third quarter 2023 earnings released

Shilpa Medicare Limited to Report Q3, 2023 Results on Feb 14, 2023

Shilpa Medicare Limited announces Launch of its New Brand Capebel (Capecitabine 1000 Mg Dispersible Tablet)

Shilpa Medicare Limited's Unit IV Facility Receives Health Canada GMP Approval

Second quarter 2023 earnings released: ₹2.15 loss per share (vs ₹2.45 profit in 2Q 2022)

Shilpa Medicare Reportedly Plans API Biz Stake Sale

Shilpa Medicare Limited to Report Q2, 2023 Results on Nov 11, 2022

Shilpa Medicare Approves Dividend for the Financial Year Ended 31 March 2022

Shilpa Medicare Limited Announces Change in Directorate

Shilpa Medicare Limited, Analytical Services Division, Nacharam, Hyderabad, Telangana Receives US FDA Clearance for the Facility

Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Shilpa Medicare Limited Announces Its Successful Innovation of First in World Topical Hemostatic Spray of Tranexamic Acid Has Received CDSCO Approval

Shilpa Medicare Limited Receives U.S Food and Drug Administration Tentative Approval for Its Anda, Tenofovir Alafenamide Tablets

Upcoming dividend of ₹1.10 per share

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

High number of new directors

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Shilpa Medicare Limited Announces Board Changes

First quarter 2023 earnings released: EPS: ₹0.10 (vs ₹0.19 in 1Q 2022)

Shilpa Medicare Limited, Annual General Meeting, Sep 28, 2022

Shilpa Medicare Limited Appoints Kamal K Sharma as an Additional Independent Director

Price target decreased to ₹355

Shilpa Medicare Limited Appoints Ritu Tiwary as Company Secretary & Compliance Officer

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Shilpa Medicare Limited to Report Fiscal Year 2022 Final Results on May 23, 2022

Shilpa Medicare Limited Via Shilpa Biologicals Private Limited Receive NoC from RCGM, Dept of Biotechnology to Approach the DCGI to Conduct Clinical Studies for its Biosimilar Aflibercept

Shilpa Medicare Limited Announces Board Resignations

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Shilpa Medicare Limited to Report Q3, 2022 Results on Feb 08, 2022

Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load

High number of new directors

Second quarter 2022 earnings released: EPS ₹2.45 (vs ₹5.57 in 2Q 2021)